SGLT2 Inhibitors: Assessing the Evidence and the Potential Impact on Future Clinical Practice.

PRLog (Press Release) - Jan. 16, 2012 - Launch date: 12st January 2012
Expiry date: 12th January 2013

EPG Online (www.epgonline.org) is pleased to announce the launch of a new CME accredited activity in the area of diabetes. This activity has been approved for 1.0 AMA PRA Category 1 Credit™. The presentation has been designed to provide endocrinologist, diabetologists, general practitioners and other healthcare professionals with current and accurate information on the use of SGLT2 inhibitors and their potential role in the management of type 2 diabetes.

The accredited presentation, available in English, German, French, Italian and Spanish, discusses the burden and impact of diabetes, current standards of care and unmet needs and the role of kidney in regulating blood glucose. The speakers (Professor John Wilding DM, FRCP, Professor Michael Stumvoll, MD, Professor Bernard Charbonnel, MD, Professor Ele Ferrannini, MD, and Professor Santiago Duran-Garcia, MD, PhD) then discuss the role of SGLT2 inhibitors in reducing hyperglycaemia; the rationale and clinical results to date and considerations for their potential clinical use.

The purpose of this activity is to provide healthcare professionals with information concerning rationale for targeting glucose reabsorption by the kidney in patients with diabetes mellitus. This information prepares participants to describe the current methods of glycaemic control in patients with type 2 diabetes mellitus and their current unmet needs. It will also allow participants to detail the evidence for SGLT2 inhibitors as therapy for type 2 diabetes mellitus and explain how SGLT2 inhibitors might be incorporated into clinical practice.

“This CME accredited webinar is an excellent addition to the diabetes resources available on epgonline.org and provides our doctors with a very valuable interactive learning experience.” Chris Cooper, EPG Health Media.

"Presented by senior diabetologists from across Europe, this programme provides a multi-lingual introduction to the SGLT2 inhibitor class of drugs.” Hilary Eadon, Strategic Consultants International.

The diabetes webinar is the most recent edition to newly redesigned website www.epgonline.org; the professional channel for doctors containing 50 disease topic homepages across all medical specialties. Forming part of the diabetes and endocrinology disease topic homepage, the webinar is accompanied by disease specific knowledge centres, drug data in 9 languages, drug updates and news, treatment guidelines, multimedia, clinical trials, journals, social media and related apps.  

EPG Online, established in 2000, is an independent website dedicated to providing its 320,000 opted-in healthcare professionals with free global access to the latest best practice, diagnosis and management guidance. This information is provided through over 110,000 pages of clinical content on the website which is operated by the UK-based digital health publisher, EPG Health Media.

This activity is jointly sponsored by Global Education Group and Strategic
Consultants International. This activity is supported by an independent medical education grant from Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.


CONTACT
Press Officer
EPG Health Media
3rd Floor - Royal Victoria House                                      
51-55 The Pantiles                                                                                        
Tunbridge Wells                                    
Kent                                                      
TN2 5TE        

E-MAIL: press@epghealthmedia.com                                            
WEB: www.epghealthmedia.com                      
TEL: 01892 526 776
FAX: 01892 527 669

For information about the accreditation of this programme please contact Global at
001-303-395-1782 or inquire@global educationgroup.com